YR ENDING DEC 2018 REV $28MIL, BOOK $1.60+-,NET INCOME AROUND .34~TRAILING 12 PE~38X,PB-8X,PSR~6X. IT IS VERY EVIDENT THAT THE MULTIPLES ARE VERY HIGH, BUT THE TECHNOLOGY, & GROWTH LEND TO THIS AGGRESSIVE PRICING.

HEMA ONLY REPORTS TWICE PER YEAR AND IN OUR OPINION SHOULD SERIOUSLY CONSIDER FILING MORE THAN 2 TWICE/YEAR..

YR ENDING DEC 2018 REV $28MIL, BOOK $1.60+-,NET INCOME AROUND .34~TRAILING 12 PE~38X,PB-8X,PSR~6X. IT IS VERY EVIDENT THAT THE MULTIPLES ARE VERY HIGH, BUT THE TECHNOLOGY, & GROWTH LEND TO THIS AGGRESSIVE PRICING. HEMA ONLY REPORTS TWICE PER YEAR AND IN OUR OPINION SHOULD SERIOUSLY CONSIDER FILING MORE THAN 2 TWICE/YEAR..

THIS BRINGS US TO OUR LATEST EXTREMELY DISCOUNTED CHEAP VALUE THAT DESERVES TO TRADE BETWEEN 3-4X THE CURRENT PRICE AND MAY VERY WELL BE BOUGHT OUT BECAUSE OF THE VERY CHEAP VALUATIONS. PLEASE VIEW OUR NEW BUY RECOMMENDATION ON ETCC. PLEASE KEEP IN MIND THE NUMBER COMPARISONS !

ANOTHER NEW BUY RECOMMENDATION-PREDICTIVE TECHNOLOGY GROUP,INC. (PRED~$2.13)

READY TO EXPLODE ~

MANY OF OUR STOCK SELECTIONS ALSO HAVE THE THE POTENTIAL TO BE BOUGHT OUT BECAUSE THEY ARE JUST TOO CHEAP.

WITHIN OUR AUGUST 31ST 2017 EMAIL ALERT WE RECOMMENDED LPAD @ .81 AND WITHIN 30 DAYS OR SO IT WAS BOUGHT OUT @ $1.00. WITHIN OUR SEPT 4TH 2018 EMAIL ALERT WE RECOMMENDED MOC @ $1.86 AND REASONED THAT IT WAS A EASY TAKE OUT CANDIDATE AND WITHIN 1 MONTH IT WAS BOUGHT OUT @ $2.85.

WE CONTINUE TO POUND THE TABLE CONCERNING A RECENT INVESTMENT IDEA (TCOR) AS A STRONG POTENTIAL BUY OUT CANDIDATE. PLEASE REVIEW RESULTS FOR CALENDAR YEAR ENDING 2018 ~ REVENUE EQUALED $91 MIL , NET INCOME/SH EQUALED .07 , BK VALUE AROUND $1.20. SOLID GROWTH OVER PRIOR YEAR WITH RESPECT TO REV AND INCOME . THE STOCK SITS @ .40 (28 MILLION SHARES OUTSTANDING~ MANAGEMENT OWN OVER 1/2). THE COMPANY RELEASES NUMBERS 4 TIMES/YEAR. ONE DAY THEY WILL BE SOLD FOR MANY TIMES THE CURRENT VALUATIONS. IT IS EASILY WORTH $2.00 VS .40

THIS BRINGS US TO OUR CURRENT BUY RECOMMENDATION WHICH IS SEVERELY UNDERVALUED AND IN OUR OPINION OFFER INVESTORS ALMOST ZERO DOWNSIDE RISK AND 3-4X UPSIDE POTENTIAL EITHER VIA BEING BOUGHT OUT OR THE EVENTUAL INTEREST FROM THE INVESTMENT HERD THAT LOOKS FOR SOLIDLY RUN COMPANIES INSTEAD OF PIE-IN-THE-SKY SWINDLES SUCH AS THE RECENT NEW ISSUE LYFT THAT IS ALREADY DOWN 20% FROM OFFERING PRICE. WILL THIS COMPANY EVER MAKE ANY MONEY? HOW ABOUT THE NEXT SOUGHT AFTER MONEY LOSER, NAMELY UBER.

WE DON'T DISLIKE "NEW ISSUES" WE JUST PREFER TO BUY THEM 5-10 YEARS LATER WHEN THEY ARE OUT OF FAVOR AND OFFER ATTRACTIVE RETURNS.

ENVIRONMENTAL TECTONICS CORP (ETCC-.72)

The company is principally engaged in the design, manufacture and sale of software driven products and services used to recreate and monitor the physiological effects of motion on humans and equipment and to control, modify, simulate and measure environmental conditions. These products include aircrew training systems ( aeromedical, tactical combat and general), disaster management systems, sterlizers (steam and gas), environmental testing products and hyperbaric chambers and other products and services that involve similar manufacturing techniques and engineering technologies. ETCC focuses on software enhancements, product extensions, new product development and new marketplace applications. Sales of its products are made principally to U.S. and foreign government agencies.

ETCC reports 4X/year. The third q is the most current filing and we anticipate the year end result ending Feb 2019 to be released during June 2019.

website~ www.etcusa.com

phone~ 215 355 9100

E-mail~ [email protected]

Total shares outstanding 9.4 million and 12k Preferred Series E which can be converted into around 6 million additional common shares. We will base our calculations using the fully diluted number of 15.5 million shares.

Around 200k options @ .68 are currently outstanding. Very tiny number.

Revenue for the 9 months equaled $33 million and net income/share equaled .10 based upon the total shares outstanding including all conversions (15.5 million).

The book value equals .73

For the 9 month comparison income equaled .10 vs .05 for fiscal 2018. Income basically doubled.

The estimates for fiscal 2019 equals $45 million and net income of .15/ based upon fully diluted shares outstanding.

Fiscal year ending 2019 est. of .15 inccome vs .12 income for fiscal 2018 results in a 20% income growth rate.

We would not be surprised if the company declared a dividend to common shares holders. At the end of fiscal 2018 the backlog was extremely strong $67.5 million. The backlog is spread among all divisions.

Let us assign a conservative PE est. 15X valuation based upon our anticipated fiscal year end 2019 income number of .15. The PE est results in a share valuation of $2.15 a far cry from the current price of .72.

If we go back and look at HEMA rev of $28 million and .34 net and compare to ETCC rev of est. $45 million and net income of .15 and then compare the pricing of shares. We will see an interested valuation for sure. HEMA is growing fast in a very 'sexy" industrial group, but does it deserve the high multiplies? It all depends upon investor sentiment. If ETCC was to trade @ 30 times earnings then the share price would explode to $4.50.

HEMA trades @ 13X book ($1.60) vs ETCC trades @ book (.73). If one were to sell 1000 shares of HEMA that investor could buy 15,000-20,000 shares of ETCC. How overvalued is HEMA or how undervalued is ETCC? It is all a matter of perception and investor tolerance of risk because of that word perception!

Another item to look at is PSR ( price to sales ratio). Strictly by the numbers~ HEMA trades @ 6X while ETCC trades at an est. of .24X. The values are @ both ends of the sprectum.

If ETCC was to trade @ $6.00/sh it would still only trade @ a PSR of 2X!

It is all about perception and perception is derived from future growth and earning potential. If the "Green New Deal" scheme ever became the Nuclear Option for America ETCC could be a $50 stock because investor perception. Instead of $50 we sit @ .72.. TLRY a "pot" stock that traded from $20 to $300 recently back down to $40+. This is deadly perception and we prefer to buy a stock that offer limited downside risk with potential buyout potential because management has not paid proper attention to their stock valuation and we can wait for investor perception to change even in a small way in order to dramatically increase the value of ETCC shares.

OVERVIEW:WE RATE ETCC WITH A STRONG BUY RECOMMENDATION AT CURRENT LEVELS. ETCC SHOULD BE AT MULTIPLY DOLLARS INSTEAD OF FLATLINE AT .70 OR SO. WE BELIEVE THAT SOME COMPANY OUT THERE IS WATCHING THIS COMPANY AND THE FACT THAT IT TRADES SO CHEAPLY. A BIG FISH COULD GOBBLE ETCC AND EASILY COULD PAY $2.00 SHARE BECAUSE IT GETS REVENUE, INCOME, UNDERVALUED ASSETS, PATENTS, CUSTOMER BASE DOMESTICALLY AS WELL AS FOREIGN AND EXPERTISE THAT HAS DECADES OF DEPTH. BUY FOR THE SHORT TERM OR LONG TERM OBJECTIVE.

stock briefs:

SIMA $2 current $8.10 pinks ~HOLD non reporting much of anything

HEMA .35 current $13.00 pinks~ reports twice a year. We believe they will eventually wake up and get listed on major exchange and then POW! BUY on any meaningful pull back. Of course if you have a large position go buy the new electric Porsche due out early 2020.

VCON. .41 current .05 pinks disaster~ there might get lucky if you believe in Unicorns and Alice in Wonderland.

CETX. $2.62 current .40 another black swan that bought 41% of VCON @ .41. Management introduced the "Smart Desk". There is hope and @.40 worth a nibble if already buried , but if not could easily offer a bounce once the seller leaves for vaca.

MOC $1.86 current bought out @ $2.85 one month after recommendation.

ARWR $2.20 current $18.00 recently upgraded with a $33 target. We are happy with our position. If market turns this has the tendency to follow and could sell off in a blink!

SPRS $1.00 current $3.00 great earning report. I think it just continues to advance. Their business model loaded with "fairy' dust. Buy

Rhodium the metal $1480/oz current $2830/oz We believe platinum, palladium and rhodium are the only place to invest in the precious metals. As mentioned in last letter gold and silver~ watching paint dry is more exciting.

SNDE/SDCJF $5.32/.30(after RS) Great Eagleford oil play, but the big problem is that parent stock trades in AU. With the weak AU dollar and the worthless AU investor's this is shamefully dead money. Oil moves up SDCJF moves down. Just plain hateful and so disappointing. NO strength for a opinion- sitting and paying and praying!

ZMTP $2.40 current $1.00 the Tariffs hurt this stock,but looks attractive @ $1.00. Need patience~company will either grow or get bought out.

CVM $1.80 current $6.00 Their drug testing neck and head cancer seems to be working and additional results is forthcoming. Very speculative. We are surprised that the company has not raised any money with the price at attractive levels for a 10 million share raise @ $5 for a quick $50 million.

TCOR .52 current .40 Pinks still believe a strong buy at current levels. reports 4X/year.

OPXS/OPXXW .70/.15 current $2.05/.65 A winner anyway you slice or dice. Slow growth but consistent. We believe a buy on any sudden pull back.

PS for long term holders do not forget the juicy .12 dividend they paid awhile back!

BSGM $1.33 current (RS 1/3)-so a $4.00 stock now $6.35. Have not really followed very closely, but regardless has worked out well.

CUO $19 current $19.50 read last newsletter . Still believe a strong buy at current levels.

AAPL $166 current $203.86 the market killed the Apple so we took a bite and found no worms .

VUZI $6 or so . current $2.67. A total dog that we wished we had let the leash go along time ago. AR is the future, but the future is not here yet and VUZI is going to need money and the sharks know it~ so they short it because they believe big dilution is coming. During the past the usually raise between $15-$25 million. This is a heavy dilution. Company should just sell and get us back into reality instead of AR ( real life wealth destroyer). Regardless, we still may average down as it sinks with the sunset. .I need a Tequila Sunrise or Harvey Wallbanger. Please sell the company!

DTGI .18 current .21 been trading a lot in the high .20's and low .30's. Great trader. If want to read full story visit January 27, 2019 email alert. Like this opportunity. Great risk reward in an exciting area of cloud services specializing in UCaas. strong buy on any weakness.

Platinum January 27 email alert buy $821 current $900 ~ BUY

Palladium January 27 email alert buy $1344 current $1402~ BUY

Predictive Technology Group, Inc. (PRED~$2.13)

Corporate phone # 757 306 6090 www.predtechgroup.com

www.predictivebiotech.com

www.predictivelabs.com

Predictive Technology Group, Inc. , through its wholly owned subsidiaries; revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases onsets and progressions. PRED'S subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

Through its' wholly -owned subsidiaries, Predictive Therapeutics and Predictive Biotech, the company focuses on four main clinical categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Human Cell and Tissue Products. Predictive Therapeutics is committed to assisting women in overcoming the devastating consequences of endometriosis via appropriate early-stage diagnosis and subsequent treatment.

TOTAL PRODUCTIVITY LOSS IN EMPLOYED WOMEN WITH ENDOMETRIOSIS AVERAGES 6.3 HOURS/WEEK, WITH THE MAJORITY OF LOST PRODUCTIVITY DUE TO PRESENTEEISM, AND THE YEARLY TOTAL COST OF ENDOMETRIOSIS HAS BEEN ESTIMATED AT $22 BILLION IN THE USA (APRIL 2018).

Endometriosis is a chronic, complex, yet relatively common gynecological disorder, reportedly affecting 7 0 million adult and adolescent females worldwide.

Predictive Therapeutics (PRx) and Predictive biotech, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics.

PRx utilization of molecular diagnostics focuses on the analysis of genes and their mutations to assess a patient's inherited risk for developing a particular disease and its progression. Additionally, PRx believes that advances in the emerging field of molecular diagnostics will improve the ability to determine which patients are subject to a greater risk of developing disease, and who therefore would benefit from preventive therapies. Molecular diagnostic products may also guide a patient's healthcare to ensure the patient receives the most appropriate treatment at the most appropriate time.

Current trends in medicine lie in the creation of new classes of drugs that treat the underlying cause, not just the symptoms of disease and may be useful in disease prevention. By understanding the genetic basis of disease and by working with strategic partners, PRx believes that it will be able to develop drugs and treatment protocols that are more effective, resulting in better patient outcomes at significantly lower costs.

The first expected diagnostic PRED, through its sub PRx, expects to commercialize a genetic diagnostic for ENDOMETRIOSIS for the fertility market. PRx then will focus development resources on its proprietary genetic based diagnostics for scoliosis and degenerative disc disease.

NHP-07- First pharma/therapeutic candidate to be developed by PRx. Management believes NHP-07 with EndoRisk** as a companion diagnostic/prognostic is the only treatment protocol that may suppress/prevent development of endometriosis and its debilitating symptoms.

Predictive biotech develops and commercializes minimally manipulated allograft products from umbilical cord and placental tissue.

HUMAN CELL AND TISSUE PRODUCTS INCLUDE:

1.CoreCyte** is a minimally manipulated human tissue allograft suspension derived from the Wharton's Jelly of the umbilical cord . CoreCyte** is processed to preserve the biological and structural integrity of Wharton's jelly for homologous use.

2.PolyCyte** is a minimally manipulated human tissue allograft suspension derived from the Wharton's jelly of the umbilical cord. PolyCyte** is processed to preserve the molecular profiles of cytokines, growth factors and proteins in Wharton's jelly for homologous use.

3.AmnioCyte Plus ** is a minimally manipulated human tissue allograft suspension derived from the extracellular matrix of the amniotic membrane. AmnioCyte Plus** is processed to preserve the cellular scaffolding proteins and cytokines in amniotic membrane for homologous use.

4. AmnioCyte** is a minimally manipulated human tissue allograft derived from amniotic fluid. AmnioCyte** is processed to preserve the molecular profile of cytokines, growth factors and proteins in amniotic fluid for homologous use.

We suggest if you want even more detailed information concerning all the additional research and development that you read the Quarterly Report (Feb 15, 2019) ending December 31, 2018. We also suggest that you visit their website and of course read the current news.

LET US TAKE A LOOK AT THE MANAGEMENT TEAM , DIRECTORS AND ADVISORY BOARD!

1.Mr, John Sorrentino~Chairman. VP and CEO of Pfizer Vaccine R&D~

2.Mr. Bradley Robinson~President. Previously President, Sagent Technologies, CEO/Co-Founder of Infusive Technologies and Director/Co-Founder of Specialized Health Products, Inc.

3. Mr. Michael Dey~Director. Executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs for Wyeth's Women's Health Care business. As President of Wyeth's WHC for 7 years. Dr Dey managed its global resources of more than $3 billion annually.

4.Mr. Simon Brewer~CFO~Served as CFO for Norbest and played integral role in the Company's sales growth to $150 million annually.

5.Mr. Paul Evans~COO~Prior he was head of all intellectual property matters for Vivint.

6.Orrin G Hatch~7 terms as U.S. Senator(42 years) from Utah

6.Mr. Barhorst ~ Financial Advisory Board ~Chair of The California State University Foundation . He retired as President and CEO of ING Financial ,LLC

7. Mr. Jay Moyes~Director~ CFO of publicly traded biomaterials company, Amedica Corp, now SINTX Tech. Also CFO during 14 year tenure at publicly traded Myraid Genetics. Myraid transitioned from 10 to more than 900 employees He was instrumental in raising more than $500 million in public and private finance .

8.Dr. Taylor, a Chief of Obstetrics and Gynecology at Yale (Scientific Advisory Board)

9. Dr. Kenneth Ward ~Chairman and CEO of Juneau Biosciences (Scientific Advisory Board)

Note: PRED recently acquired 70% of this company. See recent presser.

10. Mr. Eric Olson~Executive VP and CEO of Predictive Biotech.~ Prior CEO of Skeletal kinetics which developed and commercialized synthetic bone substitutes for Orthopedic and Spinal applications.

11. Dr. John Nelson~Chief Medical Officer~Served as President of the AMA and served on the Advisory Committee to the Director of the National institute of Health (NIH).

12. Mr Tim Lacy~President~27 years in the healthcare industry. Key role in the commercialization of PRED products and services.

NOTE: All directors and Advisory Board members do not receive any payments for their service except for recently offered 1 year options to up to 10,000,000 shares of restricted common shares at $2.07. These options only have a one year term limit to exercise. One person does have a small amount of stock options at .50 and the balance at $2.70, but only has 1 year exercise period as well.

Select financial data:

The reporting revenue derived from HCT/Ps. The Company operates in two reportable segments. HCT/Ps and diagnostics and therapeutics. Predictive Biotech's HCT/Ps are processed in the company's FDA registered lab. This segment HCT/Ps manipulates tissue products and are prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factor and general cytokines and are intended for homologous use. Predictive Technology's diagnostics and therapeutics uses data analytics for disease identification and subsequent therapeutic intervention through unique novel gene-based diagnostics, biotechnology treatments and companion therapeutics.

Revenue year-ending fiscal 18 ~ $16.2 million and net loss of $12 million.

Revenue for the 6 months ending 12/31/18 ( fiscal 19) revenues equaled $18.8 million and net loss $4.1 million. The total equity for the 6 months ending Dec 31, 2018 equaled $103 million and based upon 247 million shares outstanding. At the time of filing during Feb 2019 the outstanding shares equaled 271 million.

As of April 4, 2019 the total outstanding shares equaled 272 million. This number includes any shares used to acquire 70% of Juneau Bioscience which holds licensed technology supporting its ARTGuide** test for endometriosis and other genetic causes of infertility.

Note: Juneau had revenues not included within Dec 31, 2018 six month numbers. The stand alone revenue equaled $2.5 million for calendar year ending Dec 31, 2018 with losses of $2.4 million.

On or about March 26th 2019 PRED completes acquisition of Taueret Laboratories. The addition of CAP/CLIA lab and experienced diagnostics team form an unparalleled molecular clinical and research facility to accelerate new product development, commercialization and scale.

This $10 million dollar acquisition was paid with $1.2 million in restricted common stock and $8.5 million to be paid on or before Dec 31, 2020.

In conjunction with the acquisition, PRED invested $4.2 million in new laboratory instrumentation and resources to bolster capabilities in the 15,000 square-foot laboratory and administrative campus, which now contains all necessary infrastructure for the Company's clinical operations.

Taueret Laboratories is a privately held molecular lab focusing on human infertility , women's health, and childhood diseases and performs genetic testing using state-of-art-instrumentation.

Note: On March 28, 2019 PRED announced the completed build out of a new production lab and R&D facility for its sub company, Predictive Biotech. The newly renovated 22,000 square foot facility, located in Research Park on the University of Utah's campus, features an ISO 7 cleanroom and 18 ISO 5 production hoods.

OVERVIEW OF THE NUMBERS

$$$$$$$$$$$$$$$$$

Management comments concerning 6 month financial reporting ending Dec 31, 2018 ( fiscal 2019). Bradley C. Robinson, CEO of PRED announced the most recent quarter of nearly $11 million, up more than three-fold from the year-ago period, marking our ninth consecutive quarter of growth. He goes on to say that it puts PRED on a run rate exceeding $40 million for fiscal 2019. In addition the company generated $2 million in positive cash flow from operations(EBITDA) for the past 6 months that supported the further development and commercialization of proprietary genetic-based diagnostics and therapeutics. At the end of the second Q the company had $2.6 million cash on hand and no-long term debt.

$$$$$$$$$$$$$$$

Please keep in mind since that announcement was made there have been many additions to the growth profile of PRED.

We anticipate additional updates and projections from management near term.

BOTTOM-LINE: FROM ALL INDICATIONS WE ARE WITNESSING A HIGH TECH BIOTECH COMPANY BEING FORMED. THE CLUES SHOULD BE VERY EASY TO SPOT. THE MANAGEMENT TEAM, DIRECTORS AND ADVISORY BOARD INDICATE SERIOUS COMMITMENT FROM HIGHLY SUCCESSFUL INDIVIDUALS THAT APPEAR TO HAVE FORMED A VERY TIGHT-KNIT ORGANIZATION. IT HAS A WELL THOUGHT OUT PLAN TO GROW RAPIDLY INTO A REVENUE DRIVEN BIOTECH AND SCIENCE ORIENTED COMPANY. THE CONNECTIONS THAT MANAGEMENT MUST HAVE LEADS US TO BELIEVE THAT ADDITIONAL ACQUISITIONS ARE FORTHCOMING! WE BELIEVE THAT FILING THEIR FORM 10 TO LIST ON THE NASDAQ IS ALSO IN THE WORKS. ONCE THIS COMPANY LISTS IT IS OBVIOUS THAT REGIONAL AND MAYBE LARGER FIRMS WILL FOLLOW THE SUCCESS OF PRED!

ONE MUST ASSUME THAT AS THIS COMPANY GROWS ADDITIONAL FUNDING WILL BE NEEDED SO IT IS A NATURAL ROAD MAP THAT INVESTMENT BANKING FIRMS WILL STEP UP TO THE PLATE.

WE BELIEVE THAT PRED IS IN THE EARLY STAGES OF EXPLOSIVE GROWTH VIA ORGANIC AND BY ACQUISITION.

ALL THE PIECES OF THIS PUZZLE HAVE BEEN SET IN MOTION AND THE VISIONARY INVESTOR TYPE SHOULD BE ABLE TO GLEAN WITH A GREAT DEGREE OF CERTAINTY THAT PRED IS ON THE LAUNCH PAD!

(we have done very well with biotech companies in the past. HEMA .35 to $1300, ARWR $2.20 to $18.00 and CVM $1.80 to $6.00)

We have a strong feeling that this opportunity may very well surpass all expectations during the next 3-6 months. We rate PRED with a very STRONG BUY RECOMMENDATION with potential rapid share appreciation.

WE WISH TO THANK ALL INVESTORS THAT HAVE BEEN FOLLOWING OUR STOCK RECOMMENDATIONS FOR THE PAST 35 YEARS. S. A. ADVISORY HAS ALWAYS TRIED TO BE AS HONEST AND ETHICAL WITH RESPECT TO OUR OPINION AND RECOMMENDATIONS.